Literature DB >> 8411243

Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.

M J Ratain1, R Mick, R L Schilsky, M Siegler.   

Abstract

Keywords:  Biomedical and Behavioral Research

Mesh：

Substances：

Year:  1993        PMID： 8411243     DOI： 10.1093/jnci/85.20.1637

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  38 in total

Review 1.  Development of target-based antineoplastic agents.

Authors:  W M Stadler; M J Ratain
Journal:  Invest New Drugs       Date:  2000-02       Impact factor: 3.850

2.  Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers.

Authors:  Anton Leighton; Alice Bendix Gottlieb; Mary Beth Dorr; Daniela Jabes; Giorgio Mosconi; Claudia VanSaders; Edward J Mroszczak; Kathleen C M Campbell; Ellen Kelly
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

3.  Proposal for size justification of expanded cohort at phase-2-recommended dose.

Authors:  Nicolas Penel; Charles Fournier; Jocelyne Bérille
Journal:  Invest New Drugs       Date:  2010-02-02       Impact factor: 3.850

4.  Predictors for establishing recommended phase 2 doses: analysis of 320 dose-seeking oncology phase 1 trials.

Authors:  Nicolas Penel; Alain Duhamel; Antoine Adenis; Patrick Devos; Nicolas Isambert; Stéphanie Clisant; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2010-11-04       Impact factor: 3.850

5.  Assessing risk/benefit for trials using preclinical evidence: a proposal.

Authors:  Jonathan Kimmelman; Valerie Henderson
Journal:  J Med Ethics       Date:  2015-10-13       Impact factor: 2.903

Review 6.  Ethical issues in the development of new agents.

Authors:  C K Daugherty
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

7.  Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data.

Authors:  Julian R Molina; Scott H Kaufmann; Joel M Reid; Stephen D Rubin; Marina Gálvez-Peralta; Robert Friedman; Karen S Flatten; Kevin M Koch; Tona M Gilmer; Robert J Mullin; Roxanne C Jewell; Sara J Felten; Sumithra Mandrekar; Alex A Adjei; Charles Erlichman
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

8.  "Classical 3 + 3 design" versus "accelerated titration designs": analysis of 270 phase 1 trials investigating anti-cancer agents.

Authors:  Nicolas Penel; Nicolas Isambert; Pierre Leblond; Charles Ferte; Alain Duhamel; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2009-01-10       Impact factor: 3.850

Review 9.  Cancer stem cells: relevance to SCT.

Authors:  T Lin; R J Jones; W Matsui
Journal:  Bone Marrow Transplant       Date:  2009-02-23       Impact factor: 5.483

10.  A phase I and pharmacologic study of pyrazoloacridine (NSC 366140) and carboplatin in patients with advanced cancer.

Authors:  Alex A Adjei; Joel M Reid; Charles Erlichman; Jeff A Sloan; Henry C Pitot; Steven R Alberts; Richard M Goldberg; Lorelei J Hanson; Stacie Ruben; Scott A Boemer; Pamela Atherton; Matthew M Ames; Scott H Kaufmann
Journal:  Invest New Drugs       Date:  2002-08       Impact factor: 3.850
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.